HRAS and thyroid gland carcinoma: Of 340 well-differentiated thyroid carcinomas, 77 (22.6%) were detected with RAS variants, including 46 (13.5%) with NRAS, 25 (7.4%) with HRAS, and 6 (1.8%) with KRAS. In addition, interpatient variabilities of BRAF V600E and TERT promoter variants (C228T and C250T) were detected in 173 (50.9%) and 55 (16.2%) carcinomas, respectively, with 45 (13.2%) of them in coexistence.